Selisistat

Drug Profile

Selisistat

Alternative Names: EX-527; SEN 0014196; SEN196

Latest Information Update: 25 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Elixir Pharmaceuticals
  • Developer Siena Biotech
  • Class Amides; Antineoplastics; Carbazoles; Neuroprotectants; Small molecules
  • Mechanism of Action SIRT1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Huntington's disease

Most Recent Events

  • 20 Feb 2015 Pharmacokinetics and adverse events data from a phase I trial in Healthy volunteers released by Siena Biotech
  • 20 Feb 2015 Pharmacokinetics, pharmacodynamic and adverse events data from a phase I/II trial in Huntington's disease released by Siena Biotech
  • 31 Dec 2012 Siena Biotech completes a phase I trial in Huntington's disease in USA (NCT01485965)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top